The medical equipment manufacturer saw its revenue expand to ¥7.24 billion, up from ¥6.45 billion in the corresponding period a year earlier. This topline growth was accompanied by a sharp increase in operating profit, which reached ¥829.00 million, a significant jump from the ¥584.00 million reported previously.

Profitability and Shareholder Returns

Pretax profit for the period climbed to ¥861.00 million, according to the company’s regulatory filing. The resulting net income of ¥460.00 million brought earnings per share to ¥66.44, compared to ¥61.66 in the prior year.

Techno Medica confirmed its dividend forecast, maintaining a steady return for investors despite the earnings growth:

• The projected year-end dividend remains at ¥68.00 per share.
• Total annual dividends are expected to reach ¥68.00, matching the previous year’s payout.
• All results are calculated based on Japanese accounting standards.

The firm’s performance through December 31 reflects a period of heightened operational efficiency, with pretax margins showing marked improvement over the 2024 fiscal cycle. Management has not signaled any immediate changes to its capital allocation strategy following these results.